SAM
NUVB icon

Silvercrest Asset Management’s Nuvation Bio NUVB Stock Holding History

Silvercrest Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.8M Buy
1,021,526
+297,143
+41% +$1.45M 0.04% 433
2026
Q1 		$3.11M Buy
+724,383
New +$4.04M 0.02% 479

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Silvercrest Asset Management's NUVB Position: Q2 2026 in Review

Silvercrest Asset Management increased its Nuvation Bio (NUVB) stake by 41% in Q2 2026, buying an estimated $1.45M and bringing the position to 1,021,526 shares worth $5.8M. The position accounts for 0.04% of the portfolio, ranked #433.

Silvercrest Asset Management first reported a position in NUVB in Q1 2026 and has held it in 2 quarters since. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Silvercrest Asset Management held 1,021,526 shares of Nuvation Bio worth $5.8M as of Q2 2026.
  • Silvercrest Asset Management bought 297,143 Nuvation Bio shares in Q2 2026, an estimated $1.45M.
  • Nuvation Bio made up 0.04% of Silvercrest Asset Management's portfolio in Q2 2026, its #433 holding.
  • Silvercrest Asset Management first reported a position in Nuvation Bio in Q1 2026 and has held it in 2 quarters since.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.